Rimegepant

PBAC's latest decision on Rimegepant: Recommended with restriction (2024). Considered for Acute treatment of migraine attacks in adult patients who have not responded adequately, are intolerant or contraindicated to analgesics and at least two selective 5-hydroxytryptamine receptor agonists (triptans).

Eligible population

Adults with moderate to severe acute migraine attacks who have inadequately responded to at least 2 triptans or who are intolerant or contraindicated to triptans, who require treatment for not more than 8 acute migraine attacks of moderate to severe intensity per month, and who have also failed analgesics.

Therapy area

Neurology

Line of therapy

Later-line

Evidence base

RCT

Primary endpoint

Pain relief

Pivotal trial size

148 patients

Key trials

BHV3000-301, BHV3000-302, BHV3000-303, BHV3000-201

Comparator

placebo (as a proxy for best supportive care)

Economic model

CUA

Risk sharing

Risk-sharing arrangement in place — A three-tier risk sharing arrangement was proposed in the resubmission to manage uncertainties in rimegepant eligibility, uptake and use.

Similar precedents

• Atogepant
  similarity 0.71
• Erenumab
  similarity 0.66
• Galcanezumab
  similarity 0.66
• Eptinezumab
  similarity 0.64
• Pregabalin
  similarity 0.64
• Methadone
  similarity 0.63